SCHEMBL4880541

SCHEMBL4880541

COc1cccc(C2(C(=O)OS(N)(=O)=O)CCN(c3ccccc3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 5/20 0.48
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA9 Q16790 3/20 0.46
NPY1R P25929 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
MMP14 P50281 1/20 0.43
MAPT P10636 2/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
OPRL1 P41146 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4876644 0.86 SOAT1 (0.51) SOAT1CA12CA1CA2CA9
SCHEMBL4876722 0.86 SOAT1 (0.56) SOAT1NPY1RFFAR4USP2ALDH1A1
SCHEMBL4877226 0.86 SIGMAR1 (0.48) CA12CA1CA2CA9USP2
Hydrochloric Acid SCHEMBL4880951 0.85 SOAT1 (0.51) SOAT1CA12CA1CA2CA9
SCHEMBL4883886 0.85 L3MBTL1 (0.54) ALDH1A1SMN1; SMN2MMP9MMP13MAPT
SCHEMBL4881113 0.85 SOAT1 (0.50) SOAT1CA12CA1CA2CA9
SCHEMBL4876701 0.85 ALDH1A1 (0.50) USP2ALDH1A1CYP3A4SMN1; SMN2MAPT
SCHEMBL4876690 0.85 SOAT1 (0.54) SOAT1NPY1RFFAR4USP2ALDH1A1
SCHEMBL4876712 0.84 OPRD1 (0.46) CA12CA1CA2CA9ALDH1A1
SCHEMBL4880472 0.82 STS (0.42) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 SOAT1 502/4885CA12 2402/4885CA1 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.